Spero Therapeutics, Inc. NASDAQ:SPRO

Founder-led company

Spero Therapeutics stock price today

$1.84
+0.81
+78.64%
Financial Health
0
1
2
3
4
5
6
7
8
9

Spero Therapeutics stock price monthly change

-27.46%
month

Spero Therapeutics stock price quarterly change

-27.46%
quarter

Spero Therapeutics stock price yearly change

-26.43%
year

Spero Therapeutics key metrics

Market Cap
52.55M
Enterprise value
N/A
P/E
-1.27
EV/Sales
-24.97
EV/EBITDA
1.46
Price/Sales
0.01
Price/Book
N/A
PEG ratio
-0.02
EPS
0.43
Revenue
102.29M
EBITDA
16.08M
Income
23.40M
Revenue Q/Q
468.10%
Revenue Y/Y
108.67%
Profit margin
-1786.12%
Oper. margin
-1662.46%
Gross margin
21.86%
EBIT margin
-1662.46%
EBITDA margin
15.73%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Spero Therapeutics stock price history

Spero Therapeutics stock forecast

Spero Therapeutics financial statements

Spero Therapeutics, Inc. (NASDAQ:SPRO): Profit margin
Jun 2023 788K -11.91M -1511.93%
Sep 2023 25.47M -3.20M -12.58%
Dec 2023 71.82M 51.19M 71.27%
Mar 2024 4.20M -12.66M -301.36%
Spero Therapeutics, Inc. (NASDAQ:SPRO): Analyst Estimates
Mar 2024 4.20M -12.66M -301.36%
Sep 2025 13M -13.01M -100.09%
Oct 2025 10.5M -20.87M -198.8%
Dec 2025 25M -13.91M -55.66%
  • Analysts Price target

  • Financials & Ratios estimates

Spero Therapeutics, Inc. (NASDAQ:SPRO): Debt to assets
Jun 2023 98885000 44.10M 44.6%
Sep 2023 107101000 53.39M 49.86%
Dec 2023 182390000 75.49M 41.39%
Mar 2024 167703000 71.45M 42.61%
Spero Therapeutics, Inc. (NASDAQ:SPRO): Cash Flow
Jun 2023 -18.56M 0 0
Sep 2023 15.91M 0 220K
Dec 2023 -17.49M 0 1K
Mar 2024 5.93M 0 0

Spero Therapeutics alternative data

Spero Therapeutics, Inc. (NASDAQ:SPRO): Employee count
Aug 2023 35
Sep 2023 35
Oct 2023 35
Nov 2023 35
Dec 2023 35
Jan 2024 35
Feb 2024 35
Mar 2024 46
Apr 2024 46
May 2024 46
Jun 2024 46
Jul 2024 46

Spero Therapeutics other data

13.56% -26.07%
of SPRO is owned by hedge funds
5.09M -9.12M
shares is hold by hedge funds

Spero Therapeutics, Inc. (NASDAQ:SPRO): Insider trades (number of shares)
Period Buy Sel
Aug 2023 0 18765
Sep 2023 0 39496
Feb 2024 0 229741
Transaction Date Insider Security Shares Price per share Total value Source
Sale
SHUKLA SATH director, officer: CEO and Pres..
Common Stock 45,093 $1.45 $65,385
Sale
HAMED KAMAL officer: Chief Medical Officer
Common Stock 28,075 $1.37 $38,463
Sale
KEUTZER TIMOTHY officer: Chief Operating Officer
Common Stock 30,971 $1.36 $42,121
Sale
MAHADEVIA ANKIT director Common Stock 63,795 $1.37 $87,399
Sale
JOSEPH TAMARA L officer: Chief Legal Officer
Common Stock 30,906 $1.37 $42,341
Sale
SHUKLA SATH director, officer: CEO and Pres..
Common Stock 30,901 $1.37 $42,334
Sale
HAMED KAMAL officer: Chief Medical Officer
Common Stock 39,496 $1.27 $50,160
Sale
SHUKLA SATH director, officer: CEO and Pres..
Common Stock 4,163 $1.3 $5,412
Sale
KEUTZER TIMOTHY officer: Chief Development Offi..
Common Stock 1,854 $1.26 $2,336
Sale
JOSEPH TAMARA L officer: Chief Legal Officer
Common Stock 1,854 $1.26 $2,336
Patent
Application
Filling date: 12 Nov 2021 Issue date: 12 May 2022
Application
Filling date: 25 Jun 2019 Issue date: 12 Aug 2021
Application
Filling date: 25 Jan 2021 Issue date: 22 Jul 2021
Application
Filling date: 29 Dec 2020 Issue date: 29 Apr 2021
Application
Filling date: 6 Feb 2018 Issue date: 20 Feb 2020
Application
Filling date: 15 Dec 2017 Issue date: 16 Jan 2020
Monday, 16 December 2024
zacks.com
Friday, 15 November 2024
zacks.com
Thursday, 14 November 2024
zacks.com
globenewswire.com
Wednesday, 16 October 2024
globenewswire.com
Wednesday, 2 October 2024
globenewswire.com
Friday, 9 August 2024
seekingalpha.com
Monday, 5 August 2024
zacks.com
globenewswire.com
Monday, 29 July 2024
globenewswire.com
Monday, 8 July 2024
investorplace.com
Wednesday, 3 July 2024
globenewswire.com
Monday, 3 June 2024
globenewswire.com
Monday, 20 May 2024
https://www.defenseworld.net
Thursday, 16 May 2024
globenewswire.com
Wednesday, 15 May 2024
globenewswire.com
Wednesday, 8 May 2024
globenewswire.com
Wednesday, 1 May 2024
globenewswire.com
Tuesday, 23 April 2024
seekingalpha.com
Wednesday, 13 March 2024
Zacks Investment Research
Wednesday, 6 March 2024
GlobeNewsWire
Monday, 26 February 2024
GlobeNewsWire
Monday, 13 November 2023
Seeking Alpha
Monday, 6 November 2023
GlobeNewsWire
Wednesday, 18 October 2023
Zacks Investment Research
Wednesday, 20 September 2023
GlobeNewsWire
Wednesday, 6 September 2023
GlobeNewsWire
Tuesday, 29 August 2023
Zacks Investment Research
Zacks Investment Research
Tuesday, 22 August 2023
Zacks Investment Research
  • What's the price of Spero Therapeutics stock today?

    One share of Spero Therapeutics stock can currently be purchased for approximately $1.84.

  • When is Spero Therapeutics's next earnings date?

    Unfortunately, Spero Therapeutics's (SPRO) next earnings date is currently unknown.

  • Does Spero Therapeutics pay dividends?

    No, Spero Therapeutics does not pay dividends.

  • How much money does Spero Therapeutics make?

    Spero Therapeutics has a market capitalization of 52.55M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 99.13% to 96.74M US dollars.

  • What is Spero Therapeutics's stock symbol?

    Spero Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "SPRO".

  • What is Spero Therapeutics's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Spero Therapeutics?

    Shares of Spero Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Spero Therapeutics's key executives?

    Spero Therapeutics's management team includes the following people:

    • Dr. Ankit Mahadevia M.D., MBA Co-Founder, Chief Executive Officer, Pres & Director(age: 44, pay: $966,830)
    • Dr. David A. Melnick M.D. Chief Medical Officer(age: 73, pay: $647,310)
    • Ms. Cristina Larkin Chief Operating Officer(age: 55, pay: $639,360)
  • Is Spero Therapeutics founder-led company?

    Yes, Spero Therapeutics is a company led by its founder Dr. Ankit Mahadevia M.D., MBA.

  • How many employees does Spero Therapeutics have?

    As Jul 2024, Spero Therapeutics employs 46 workers.

  • When Spero Therapeutics went public?

    Spero Therapeutics, Inc. is publicly traded company for more then 7 years since IPO on 2 Nov 2017.

  • What is Spero Therapeutics's official website?

    The official website for Spero Therapeutics is sperotherapeutics.com.

  • Where are Spero Therapeutics's headquarters?

    Spero Therapeutics is headquartered at 675 Massachusetts Avenue, Cambridge, MA.

  • How can i contact Spero Therapeutics?

    Spero Therapeutics's mailing address is 675 Massachusetts Avenue, Cambridge, MA and company can be reached via phone at 857 242 1600.

Spero Therapeutics company profile:

Spero Therapeutics, Inc.

sperotherapeutics.com
Exchange:

NASDAQ

Full time employees:

46

Industry:

Biotechnology

Sector:

Healthcare

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

675 Massachusetts Avenue
Cambridge, MA 02139

CIK: 0001701108
ISIN: US84833T1034
CUSIP: 84833T103